Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review

The approved biologics targeting interleukin (IL)-23 p19 for the treatment of moderate-to-severe plaque psoriasis, including guselkumab, tildrakizumab, and risankizumab, have generally favorable safety profiles. The aim of the current review is to describe in detail the safety of these selective inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Blauvelt, Andrew, Chiricozzi, Andrea, Ehst, Benjamin D., Lebwohl, Mark G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329957/
https://www.ncbi.nlm.nih.gov/pubmed/37330926
http://dx.doi.org/10.1007/s12325-023-02568-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329957/
https://www.ncbi.nlm.nih.gov/pubmed/37330926
http://dx.doi.org/10.1007/s12325-023-02568-0

Ejemplares similares